C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD) using its proprietary TORPEDO platform to design small-molecule protein degraders. Its lead oncology candidates include cemsidomide (IKZF1/3 degrader for multiple myeloma) and CFT8919 (EGFR L858R degrader for NSCLC). The company also pursues inflammation, neuroinflammation, and neurodegeneration indications and maintains collaborations with Merck KGaA, Roche, Betta Pharma, and Pfizer.
expected 2026-12-25
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001628280-26-012000 | EDGAR | 94K words |
| 2025-02-27 | 2024-12-31 | 0001628280-25-008433 | EDGAR | 95K words |
| 2024-02-22 | 2023-12-31 | 0001628280-24-006144 | EDGAR | 94K words |
| 2023-02-23 | 2022-12-31 | 0001628280-23-004711 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001564590-22-006499 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012531 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001628280-26-055494 | EDGAR | 57K words |
| 2025-11-06 | 2025-09-30 | 0001628280-25-049854 | EDGAR | 61K words |
| 2025-08-07 | 2025-06-30 | 0001628280-25-038587 | EDGAR | 58K words |
| 2025-05-07 | 2025-03-31 | 0001628280-25-022866 | EDGAR | 56K words |
| 2024-10-31 | 2024-09-30 | 0001628280-24-044411 | EDGAR | 57K words |
| 2024-08-01 | 2024-06-30 | 0001628280-24-033882 | EDGAR | 56K words |
| 2024-05-08 | 2024-03-31 | 0001628280-24-021368 | EDGAR | 57K words |
| 2023-11-01 | 2023-09-30 | 0001628280-23-035793 | EDGAR | 60K words |
| 2023-08-08 | 2023-06-30 | 0001628280-23-027941 | EDGAR | 59K words |
| 2023-05-04 | 2023-03-31 | 0001628280-23-015459 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001628280-22-027985 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-020886 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-25 | 0001628280-26-063497 | EDGAR | 5K words |
| 2026-08-11 | 0001628280-26-055490 | EDGAR | 3K words |
| 2026-02-26 | 0001628280-26-011971 | EDGAR | 2K words |
| 2026-01-14 | 0001628280-26-002010 | EDGAR | 2K words |
| 2025-11-06 | 0001628280-25-049850 | EDGAR | 3K words |
| 2025-10-16 | 0001193125-25-241591 | EDGAR | 28K words |
| 2025-10-16 | 0001628280-25-045157 | EDGAR | 6K words |
| 2025-10-01 | 0001628280-25-043290 | EDGAR | 1K words |
| 2025-09-22 | 0001628280-25-042245 | EDGAR | 7K words |
| 2025-08-07 | 0001628280-25-038576 | EDGAR | 2K words |
110 total filings indexed. 82 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001662579 |
| Ticker | CCCC |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.c4therapeutics.com |
| Listed | 2020-10-02 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CCCC (~200 tokens, structured JSON with cryptographic provenance)